Oruka Therapeutics (FRA:HQ1) EV-to-FCF : -8.30 (As of Jul. 13, 2025)

Oruka Therapeutics EV-to-FCF Chart

Competitive Comparison of Oruka Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Oruka Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's EV-to-FCF falls into.

Oruka Therapeutics EV-to-FCF Calculation

Oruka Therapeutics's EV-to-FCF for today is calculated as:

Oruka Therapeutics's current Enterprise Value is €160.30 Mil.
Oruka Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-19.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics  (FRA:HQ1) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Oruka Therapeutics's PE Ratio (TTM) for today is calculated as:

Oruka Therapeutics's share price for today is €11.90.
Oruka Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.388.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Oruka Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description